Literature DB >> 3536547

Preparation of red-blood-cell-depleted marrow for ABO-incompatible marrow transplantation by density-gradient separation using the IBM 2991 blood cell processor.

N R Jin, R Hill, G Segal, B Still, F B Petersen, D Amos, C D Buckner, R Clift, W Bensinger, P Martin.   

Abstract

Thirty patients who had major ABO blood group incompatibility with their HLA-matched donors underwent allogeneic marrow transplantation after removal of red blood cells (RBC) from donor marrow by Ficoll-Diatrazoate (F-D) separation using the IBM 2991 blood cell processor. We selected the IBM 2991 because we were interested in obtaining information about RBC-depleted mononuclear cells for monoclonal antibody and complement incubation of marrow. The median residual marrow RBC volume was 2.6 ml (1.2% of the original volume) and marrow infusion was well tolerated in every instance. The median doses of nucleated and mononuclear cells were 8.7 X 10(7)/kg and 2.2 X 10(7)/kg recipient weight, respectively, representing median marrow total nucleated and mononuclear cell losses of 63.4% and 52.9%, respectively. The median CFU-GM loss was 52.4%. Four patients died 13-21 days after marrow infusion and were unevaluable for engraftment. One patient failed to achieve engraftment and received a second transplant on day 36 from a second donor. One patient with myelofibrosis had poor engraftment and died on day 177 with low peripheral blood counts. For evaluable patients, no significant differences were observed in the rate of recovery of peripheral blood granulocyte or platelet counts between those receiving RBC-depleted marrow or ABO-matched unprocessed marrow. However, posttransplant red cell transfusion requirements were increased and transfusion independence delayed in patients receiving RBC-depleted marrow as compared to patients receiving unprocessed marrow. We concluded that red cell depletion using the IBM 2991 was effective in removing red cell, but resulted in significant and variable hematopoietic cell losses which may have contributed to graft failure in at least one patient. Such cell losses appear to be inherent in both manual and semiautomated methods for F-D cell separation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3536547

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  5 in total

Review 1.  The processing of stem cell concentrates from the bone marrow in ABO-incompatible transplants: how and when.

Authors:  Nicola Daniele; Maria Cristina Scerpa; Cecilia Rossi; Alessandro Lanti; Gaspare Adorno; Giancarlo Isacchi; Francesco Zinno
Journal:  Blood Transfus       Date:  2013-11-21       Impact factor: 3.443

2.  RBC depletion from a PBSC graft.

Authors:  H Bonig; G Bug
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

3.  Comparison of five methods for concentrating progenitor cells in human marrow transplantation.

Authors:  A Dragani; A Angelini; A Iacone; D D'Antonio; G Torlontano
Journal:  Blut       Date:  1990-05

4.  Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.

Authors:  Gordana Tomac; Ines Bojanić; Sanja Mazić; Ivana Vidović; Mirela Raos; Branka Golubić Ćepulić; Ranka Serventi Seiwerth; Jadranka Kelečić; Boris Labar
Journal:  Blood Transfus       Date:  2017-04-19       Impact factor: 3.443

5.  Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC.

Authors:  Soo-Zin Kim-Wanner; Gesine Bug; Juliane Steinmann; Salem Ajib; Nadine Sorg; Carolin Poppe; Milica Bunos; Eva Wingenfeld; Christiane Hümmer; Beate Luxembourg; Erhard Seifried; Halvard Bonig
Journal:  J Transl Med       Date:  2017-08-11       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.